Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools.
about
SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphatesHydroxyurea inhibits the transactivation of the HIV-long-terminal repeat (LTR) promoterInhibition of ribonucleotide reductase by 2'-substituted deoxycytidine analogs: possible application in AIDS treatmentEvaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replicationIncreased activation of the combination of 3'-azido-3'-deoxythymidine and 2'-deoxy-3'-thiacytidine in the presence of hydroxyureaInfluence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutant frequencies.3'-Azido-3'-deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency virus type 1.Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells.Deoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rateExploiting drug repositioning for discovery of a novel HIV combination therapyTransduction of interphase cells by avian sarcoma virus.L1 retrotransposition in nondividing and primary human somatic cells.Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcriptionG-->A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription.Inhibitory effect of nitric oxide on the replication of a murine retrovirus in vitro and in vivo.Reactivation of thymidine kinase-defective herpes simplex virus is enhanced by nucleosideInduction of mutations in Drosophila melanogaster gypsy retroelements by modulation of intracellular deoxynucleoside triphosphate pools in vivoEndogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells.Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector.Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations.Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase.Cyclin D3-dependent control of the dNTP pool and HIV-1 replication in human macrophagesHuman immunodeficiency virus (HIV) latency: the major hurdle in HIV eradicationIntravirion reverse transcripts in the peripheral blood plasma on human immunodeficiency virus type 1-infected individuals.In search of a function for the most frequent naturally-occurring length polymorphism (MFNLP) of the HIV-1 LTR: retaining functional coupling, of Nef and RBF-2, at RBEIII?Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors.HIV-1 transcription and latency: an update.Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture.Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector.A candidate live inactivatable attenuated vaccine for AIDS.Curing HIV: Pharmacologic approaches to target HIV-1 latency.Cellular and molecular mechanisms involved in the establishment of HIV-1 latency.Synthesis of virus-specific high-mobility DNA after temperature upshift of SC-1 cells chronically infected with moloney murine leukemia virus mutant ts1.Lentivirus gene transfer in murine hematopoietic progenitor cells is compromised by a delay in proviral integration and results in transduction mosaicism and heterogeneous gene expression in progeny cells.Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes.Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV.Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequenciesMolecular characterization of preintegration latency in human immunodeficiency virus type 1 infection.Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase
P2860
Q24624362-90871AD6-7BB4-494B-8F89-27292CCB088EQ28344235-CA1022A3-3B30-4D69-A56E-A62FA81943E9Q28369408-9C1C8930-CD5F-4F2C-AF9E-A8BF04662C2CQ28378991-95525537-2979-4456-B3E7-A89CE0531A17Q28379471-9502680E-5750-4BF9-9AEE-6576C6242B01Q30453160-B44B56B1-313B-4437-9904-3D8D586958BAQ30453467-E1369E3D-1A7B-4DDC-8A6B-402CD9BBB2FCQ33783211-EC0D36B2-E350-4739-9525-3A9038440E93Q33784748-99F97D5F-018E-46A2-BC47-57D01A0212A3Q34124794-B2545D38-E8FA-492C-B386-22E7A3E474B4Q34364782-49179B11-3AC3-4919-BA84-174B1128273BQ34650044-E4ACB52F-5DEB-467D-9BB5-42FC10A21322Q35122784-D87533BB-DA67-4B0D-9E08-A837024C42F4Q35154921-4A5ACA5B-3805-43E7-B1BC-48D90A63A665Q35850897-0EF394C0-BF5F-4D4E-9E21-27C56C5631C7Q35855478-40995413-A8ED-415C-A009-D0819A2492A3Q35857412-381470A1-09F6-499F-9AB1-FF225B9F3AC9Q35859899-A29BC7A5-57A4-4C85-ACFE-9CD1D0137057Q35891440-18705BFE-13DD-4CE7-B8BD-8A9C1570E7D8Q35905947-19B7DCAC-6A71-45AB-82AD-4FC9C961691CQ35938679-A141B9D1-A5D2-4577-BC4C-FD6ADB7D4E93Q36172087-739FA160-4F7C-4FED-904C-624C5AE10505Q36186478-FF811977-709E-4103-854D-AC13ECD95DE1Q36330062-55012D6A-B6B5-436D-9A97-65DF861F70D6Q36637426-5B404133-4534-4601-B776-D643273E1571Q36858891-F0BF9813-9363-45F9-8A6D-68078E98266BQ36954062-EB694DA4-BE8A-4E2E-B6B5-09FAD654A760Q36976156-F9C7B743-C47D-4E1F-9E9C-DF1102871CF9Q37199040-E9AC0EA3-8572-41B2-BA41-BE48EA674642Q37251114-B5FE52BA-B970-4905-9186-F175DB402112Q37364176-198C8B70-F882-4C55-8E1A-9B69434FAE54Q37645582-15372020-A67E-4A5D-A3DD-F9A79451A7A8Q38078562-7B5FA52C-F186-457A-A813-E6267831F3A1Q39592409-E0B002AC-A649-4AB0-BADC-1EC16CFEAF3DQ39593815-26DD2449-1BC0-418B-98C5-FEDDA30DB235Q39595263-4409ACA4-F9AE-4119-8385-1AA162650EE5Q39603104-598B08CB-4108-48E0-A6F8-36A44CAA1128Q39684476-4885CA3F-3BDD-4F5F-B888-1FA2A8EEFE94Q39686599-F514FE01-29DC-409B-BAD1-0CA7AA2D6188Q39785298-2914A943-5008-4094-867F-CDBE81BE03AE
P2860
Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Restriction and enhancement of ...... nucleoside triphosphate pools.
@en
type
label
Restriction and enhancement of ...... nucleoside triphosphate pools.
@en
prefLabel
Restriction and enhancement of ...... nucleoside triphosphate pools.
@en
P2093
P2860
P50
P1433
P1476
Restriction and enhancement of ...... ynucleoside triphosphate pools
@en
P2093
P2860
P304
P407
P577
1994-01-01T00:00:00Z